Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
50 articles scientifiques publiés — un praticien à la pointe de la recherche
Référence presse grand public
Cité 2 fois dans les médias — pédagogie reconnue
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Médecin engagé dans la recherche académique — 3 publications référencées dans les bases scientifiques internationales, contribuant aux travaux sur protease and inhibitor mechanisms et multiple myeloma research and treatments.
Thématiques principales
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Affiliations FR : Électricité de France (France)
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Seasonal and climatic influence on respiratory infections in children with cystic fibrosis
2024ArticleScientific Reports
Intimacy and sexual life of females with cystic fibrosis
2024ArticleJournal of Cystic Fibrosis
High Susceptibility for Cystic Fibrosis Human Airway Gland Cells to Produce IL-8 Through the IκB Kinase α Pathway in Response to Extracellular NaCl Content
2023ArticleJournal of Immunology
Use of 2,6-diaminopurine as a potent suppressor of UGA premature stop codons in cystic fibrosis
2023ArticleMolecular Therapy
Safety and pharmacokinetics of Roscovitine (Seliciclib) in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa, a randomized, placebo-controlled study
2022ArticleJournal of Cystic Fibrosis
Osteoclastogenesis and sphingosine-1-phosphate secretion from human osteoclast precursor monocytes are modulated by the cystic fibrosis transmembrane conductance regulator
2021ArticleBiochimica et Biophysica Acta - Molecular Basis of Disease
Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function
2020ArticleJournal of Cystic Fibrosis
Real-Life Safety and Effectiveness of Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis
2020ArticleAmerican Journal of Respiratory and Critical Care Medicine
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Ouest-France · 20/02/2026
<a href="https://news.google.com/rss/articles/CBMitgJBVV95cUxOMFh3UUJnenV0ZUJWdG8zMFFwdUtNN1A2cXBfY2E1NDdBYWNSMlVhMU5pamJkLVJHUXVjQjBPUHRDTGVqYjk1RHRtWGM3LXRqNnk1Wk5wRUlFQUpJYTB5N1VHX1ZvN1VtSHBsd21SWXhVSkVoa1d6dzYwMHo5SC16SUFZX0x0UnVXWkpjRXVpUHhiN3VNeVFyTW1HNnZVVG13dHUyeGx4UGdPQzRMb2NYLU9WdDljOWlMaU
📰 ina.fr · 20/10/2003
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQMG1wZWU2YW1rUEJ2ZjlfYk8tZ054bDBWRXFZN3F1VFNlWndHVm1vald1YklFWkZnby1CZ3Q4aENOZ1UtZ01oQmZ0UmlLZ1BiRW5wMGVhNWR5YUNLMGhjVnpOczdzN1Z3ZTB2WS1SMkstMlY1Q0VVZE5NQ09kNU9jVlNiaFFpQzQtd3FYcElOTjRudS1DM2RWdG8tRzRNV2xhLUNfS2hzSjVxYnVaQ2xfZy10REhHSmNk?o
Antimicrobial agents and chemotherapy · 2012
ABSTRACT Aspergillus fumigatus is the most frequent fungus found in the sputum of cystic fibrosis (CF) subjects. Itraconazole is prescribed for allergic bronchopulmonary aspergillosis (ABPA) or Aspergillus bronchitis in CF subjects. We hypothesized that A. fumigatus isolates in the sputum of CF subjects with previous exposure to itraconazole was associated with higher prevalence of azole resistance. From June 2010 to April 2011, sputum samples from adult CF subjects at Cochin University Hospital (France) were examined systematically for the detection of A. fumigatus . MICs of A. fumigatus isolates against azoles were screened using Etest, and reduced susceptibility to azoles was confirmed using the CLSI broth microdilution method. A. fumigatus was isolated from the sputum of 131/249 (52.6%) adult CF subjects, and 47/131 (35.9%) subjects had received previous treatment with itraconazole. Reduced A. fumigatus susceptibility to itraconazole (MIC, ≥2 mg/liter) was confirmed in 6/131 (4.6%) subjects. All 6 isolates also had reduced susceptibility to posaconazole (MIC, ≥0.5 mg/liter), and 3/6 isolates had reduced susceptibility to voriconazole (MIC, ≥2 mg/liter). Mutations in the cyp51A gene were detected at positions previously implicated to cause resistance in 5 isolates. Azole-resistant A. fumigatus isolates were found in 5/25 (20%) subjects exposed to itraconazole within the previous 3 years. High rates of azole-resistant A. fumigatus isolates were present in adult CF subjects and were associated with recent itraconazole exposure. Although the clinical implications of these findings will require further studies, the cautious use of itraconazole in adult CF subjects can be recommended.
American journal of respiratory and critical care medicine · 2020
Abstract Rationale Lumacaftor–ivacaftor is a CFTR (cystic fibrosis transmembrane conductance regulator) modulator combination recently approved for patients with cystic fibrosis (CF) homozygous for the Phe508del mutation. Objectives To evaluate the safety and effectiveness of lumacaftor–ivacaftor in adolescents (≥12 yr) and adults (≥18 yr) in a real-life postapproval setting. Methods The study was conducted in the 47 CF reference centers in France. All patients who initiated lumacaftor–ivacaftor from January 1 to December 31, 2016, were eligible. Patients were evaluated for lumacaftor–ivacaftor safety and effectiveness over the first year of treatment following the French CF Learning Society’s recommendations. Measurements and Main Results Among the 845 patients (292 adolescents and 553 adults) who initiated lumacaftor–ivacaftor, 18.2% (154 patients) discontinued treatment, often owing to respiratory (48.1%, 74 patients) or nonrespiratory (27.9%, 43 patients) adverse events. In multivariable logistic regression, factors associated with increased rates of discontinuation included adult age group, percent predicted FEV1 (ppFEV1) less than 40%, and numbers of intravenous antibiotic courses during the year before lumacaftor–ivacaftor initiation. Patients with continuous exposure to lumacaftor–ivacaftor showed an absolute increase in ppFEV1 (+3.67%), an increase in body mass index (+0.73 kg/m2), and a decrease in intravenous antibiotic courses by 35%. Patients who discontinued treatment had significant decrease in ppFEV1, without improvement in body mass index or decrease in intravenous antibiotic courses. Conclusions Lumacaftor–ivacaftor was associated with improvement in lung disease and nutritional status in patients who tolerated treatment. Adults who discontinued lumacaftor–ivacaftor, often owing to adverse events, were found at high risk of clinical deterioration.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2013
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Journal of health psychology · 2025 · Journal Article
Jacob A, Hubert D, Brain C, Grenet D, et al.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2025 · Journal Article
Simonnet Bisson F, Fauvernier M, Belleguic C, Boucher ID, et al.
Molecular therapy : the journal of the American Society of Gene Therapy · 2023 · Journal Article
Leroy C, Spelier S, Essonghe NC, Poix V, et al.
Biochimica et biophysica acta. Molecular basis of disease · 2021 · Clinical Trial
Jourdain ML, Sergheraert J, Braux J, Guillaume C, et al.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021 · Journal Article
Burgel PR, Durieu I, Chiron R, Mely L, et al.
ERJ open research · 2019 · Journal Article
Bry C, Hubert D, Reynaud-Gaubert M, Dromer C, et al.
European radiology · 2018 · Journal Article
Chassagnon G, Martin C, Burgel PR, Hubert D, et al.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2018 · Journal Article
Burnet E, Hubert D, Champreux J, Honoré I, et al.
PloS one · 2017 · Journal Article
Benhabiles H, Gonzalez-Hilarion S, Amand S, Bailly C, et al.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2017 · Journal Article
Hubert D, Chiron R, Camara B, Grenet D, et al.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2016 · Journal Article
Sermet-Gaudelus I, Delion M, Durieu I, Jacquot J, et al.
The clinical respiratory journal · 2016 · Journal Article
Viel M, Hubert D, Burgel PR, Génin E, et al.
Infection and drug resistance · 2016 · Review
Burgel PR, Paugam A, Hubert D, Martin C
The European respiratory journal · 2016 · Letter
Chassagnon G, Hubert D, Fajac I, Burgel PR, et al.
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2016 · Journal Article
Gaitch N, Hubert D, Gameiro C, Burgel PR, et al.
Respiratory medicine · 2016 · Journal Article
Girault A, Blanc J, Gayet V, Goffinet F, et al.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2016 · Case Reports
Coolen N, Gouya H, Kanaan R, Honoré I, et al.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2016 · Journal Article
Martin C, Hamard C, Kanaan R, Boussaud V, et al.
BMC infectious diseases · 2016 · Journal Article
Bucher J, Boelle PY, Hubert D, Lebourgeois M, et al.
La Revue du praticien · 2015 · English Abstract
Hubert D
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2015 · Journal Article
Coolen N, Morand P, Martin C, Hubert D, et al.
The journal of vascular access · 2015 · Journal Article
Dupont C, Gouya H, Panzo R, Hubert D, et al.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2015 · Journal Article
Munck A, Kheniche A, Alberti C, Hubert D, et al.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis · 2014 · Journal Article
Stankovic Stojanovic K, Hubert D, Leroy S, Dominique S, et al.
BMC pulmonary medicine · 2014 · Comparative Study
Balloy V, Thévenot G, Bienvenu T, Morand P, et al.
Journal of human genetics · 2014 · Journal Article
Martinez B, Heller M, Gaitch N, Hubert D, et al.
Respiratory medicine · 2013 · Journal Article
Martin C, Chapron J, Hubert D, Kanaan R, et al.
Antimicrobial agents and chemotherapy · 2013 · Journal Article
Tazi A, Chapron J, Touak G, Longo M, et al.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2013 · Journal Article
Hubert D, Réglier-Poupet H, Sermet-Gaudelus I, Ferroni A, et al.
Journal of medical genetics · 2013 · Journal Article
Thauvin-Robinet C, Munck A, Huet F, de Becdelièvre A, et al.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2012 · Journal Article
Laborde-Castérot H, Donnay C, Chapron J, Burgel PR, et al.
PloS one · 2012 · Journal Article
d'Alessandro E, Hubert D, Launay O, Bassinet L, et al.
Journal of hepatology · 2011 · Journal Article
Chryssostalis A, Hubert D, Coste J, Kanaan R, et al.
Clinics and research in hepatology and gastroenterology · 2011 · Case Reports
Prost à la Denise J, Hubert D, Gaudric M, Scatton O, et al.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2011 · Journal Article
Bals R, Hubert D, Tümmler B
Journal of clinical microbiology · 2011 · Case Reports
Morand PC, Burgel PR, Carlotti A, Desmazes-Dufeu N, et al.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2011 · Journal Article
Hubert D, Brunswick P, Calvet JH, Dusser D, et al.
International archives of occupational and environmental health · 2010 · Journal Article
Laurent O, Metz-Flamant C, Rogel A, Hubert D, et al.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2022 · Journal Article
Meijer L, Hery-Arnaud G, Leven C, Nowak E, et al.
The lancet. Diabetes & endocrinology · 2018 · Comparative Study
Ballmann M, Hubert D, Assael BM, Staab D, et al.
Pulmonary therapy · 2021 · Published Erratum
Hubert D, Marguet C, Benichou J, DeSouza C, et al.
Pulmonary therapy · 2021 · Journal Article
Hubert D, Marguet C, Benichou J, DeSouza C, et al.
American journal of respiratory and critical care medicine · 2020 · Journal Article
Burgel PR, Munck A, Durieu I, Chiron R, et al.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2022 · Journal Article
Meijer L, Hery-Arnaud G, Leven C, Nowak E, et al.
American journal of respiratory and critical care medicine · 2020 · Journal Article
Burgel PR, Munck A, Durieu I, Chiron R, et al.
Pediatric pulmonology · 2017 · Journal Article
Nové-Josserand R, Grard S, Auzou L, Reix P, et al.
Antimicrobial agents and chemotherapy · 2012 · Journal Article
Burgel PR, Baixench MT, Amsellem M, Audureau E, et al.
The European respiratory journal · 2022 · Journal Article
Campredon A, Battistella E, Martin C, Durieu I, et al.
Pediatric pulmonology · 2017 · Journal Article
Nové-Josserand R, Grard S, Auzou L, Reix P, et al.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021 · Journal Article
Coucke R, Chansard A, Bontemps V, Grenet D, et al.
(A) Denaturing high performance liquid chromatography patterns of polymerase chain reaction products corresponding to exon 5 and 7 of : DHPLC profile corresponding to normal exon sequence (control), and altered DHPLC because of a substitution
(B) Fluorescence sequence analysis of exon 5 and exon 7 of the gene, using the forward primer. Arrows indicate position of the p.Asn288Ser and p.Pro369Thr mutations in exon 5 and 7, respectively.<b>Copyright information:
Surfactant vesicles in templating approaches
(A) Denaturing high performance liquid chromatography patterns of polymerase chain reaction products corresponding to exon 5 and 7 of : DHPLC profile corresponding to normal exon sequence (control), and altered DHPLC because of a substitution
(B) Fluorescence sequence analysis of exon 5 and exon 7 of the gene, using the forward primer. Arrows indicate position of the p.Asn288Ser and p.Pro369Thr mutations in exon 5 and 7, respectively.<b>Copyright information:
Collaboratory: A Solution For Shared Use Of Instruments Over Secure Internet Connections
Mc 2009. Microscopy Conference, Graz, Austria. 30 August - 4 September 2009. First Joint Meeting Of Dreiländertagung And Multinational Congress On Microscopy.
Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization
<strong>Article full text</strong> <br> The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online
Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization
<strong>Article full text</strong> <br> The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
PloS one · 2014 · Journal Article
Hubert D, Soubeiran L, Gourmelon F, Grenet D, et al.
BMC pediatrics · 2014 · Comparative Study
Ballmann M, Hubert D, Assael BM, Kronfeld K, et al.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2018 · Journal Article
Hubert D, Dehillotte C, Munck A, David V, et al.
✨ Profil synthétique
IA · 20/05/2026MME Dominique HUBERT est une rhumatologue avec des publications dans le domaine de la rhumatologie et des recherches sur les maladies osseuses. Ses travaux de recherche portent sur des sujets variés, notamment la pharmacovigilance et l'épidémiologie. Elle a un h-index de 2 selon OpenAlex, basé sur 3 publications.
Expertises présumées
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.